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Abstract
Purpose: Various studies have examined the association between serum vitamin D levels and different cancers; however,
this is the first prospective study of this association with melanoma risk. The aim of this study is to investigate the
association between serum vitamin D [25(OH)D] levels and melanoma in a cohort of older, middle-aged Finnish male
smokers.
Methods: We conducted a nested case-control study within the Alpha-Tocopherol Beta-Carotene Cancer Prevention (ATBC)
Study. From the ATBC cohort, 368 subjects were chosen for our study; 92 participants that developed melanoma and 276
matched control subjects. At study baseline, lifestyle questionnaires and blood samples were collected. Serum 25(OH)D was
modeled as three sets of categorical variables: clinically-defined categories, season-specific quartiles and season-adjusted
residual quartiles. Conditional logistic regression was used to obtain odds ratios (ORs) and 95% confidence intervals (95%
CIs) to estimate the association between circulating vitamin D and melanoma risk.
Results: Overall no association of serum 25(OH)D and melanoma risk was observed. A decreased risk of developing
melanoma was observed in the middle categories compared to the lowest category, albeit not significant.
Conclusion: Results indicate no association between serum 25(OH)D levels and melanoma. Additional studies, including
possibly consortium efforts, are needed to investigate the association between serum 25(OH)D levels and risk of melanoma
in larger, more diverse study populations.
Citation: Major JM, Kiruthu C, Weinstein SJ, Horst RL, Snyder K, et al. (2012) Pre-Diagnostic Circulating Vitamin D and Risk of Melanoma in Men. PLoS ONE 7(4):
e35112. doi:10.1371/journal.pone.0035112
Editor: Yiqing Song, Brigham & Women’s Hospital, and Harvard Medical School, United States of America
Received December 8, 2011; Accepted March 12, 2012; Published April 25, 2012
This is an open-access article, free of all copyright, and may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for
any lawful purpose. The work is made available under the Creative Commons CC0 public domain dedication.
Funding: The Alpha-Tocopherol, Beta-Carotene Cancer Prevention (ATBC) Study is supported by the Intramural Research Program of the National Cancer
Institute, NIH, and by US Public Health Service contracts N01-CN-45165, N01-RC-45035, N01-RC-37004, and HHSN261201000006C from the National Cancer
Institute, NIH, DHHS. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. Ronald L. Horst is
an employee of Heartland Assays, Inc., and Kirk Snyder is an analytic programmer employed by Information Management Services, Inc. These authors played a
role in performing the experiments and analysis of the data.
Competing Interests: Dr. Ronald Horst is the President and Chief Executive Officer of Heartland Assays, Inc., where the 25(OH)D concentrations were measured.
Kirk Snyder is an analytic programmer employed by Informations Management Systems, Inc. There are no patents, products in development, or marketed
products to declare. This does not alter the authors’ adherence to all the PLoS ONE policies on sharing data and materials..
* E-mail: jacqueline.major@nih.gov
. These authors contributed equally to this work.
Introduction
Skin cancer is the most common cancer in the United States,
with malignant melanoma being the most lethal and clinically
invasive form resulting from transformation of melanocytes in skin
(ocular and intestinal primaries also occur) [1]. The incidence of
melanoma has more than doubled in the past 20 years, and among
men, it is the fifth most common cancer in the U.S. [2]. Risk of
developing melanoma increases with age and is higher among men
and fair-skinned individuals; one in 39 Caucasian men develops
melanoma in their lifetime. The primary etiologic factor for
melanoma is solar ultraviolet (UV) radiation exposure [3–5], but
interest in the potential role of circulating high vitamin D
concentrations has increased owing in part to recently observed
associations with reduced melanoma tumor progression and
improved survival [6–8].
Vitamin D status is contributed to by ultraviolet B (UVB)
exposure from sunlight and by diet and supplements [9,10].
Vitamin D is first metabolized in the liver to 25-hydroxyvitamin D
[25(OH)D], and then in the kidney and other organs to its active
form, 1,25-dihydroxycholecalciferol [1,25(OH)D]. 1,25(OH)D is
essential to calcium homeostasis and functions by regulating cell
proliferation and differentiation in various organs [11]. Circulating
levels of 25(OH)D serves as a marker of vitamin D status based on
its accessibility and precursor function to hormonal form,
1,25(OH)D [12,13]. Although some prospective studies suggest
that high levels of circulating 25(OH)D may be associated with
decreased risk of colorectal cancer, and possibly breast cancer [9],
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melanoma cell lines, in vitro studies indicate 1,25(OH)D inhibits
cell growth [14,15]. Case-control studies have found associations
with improved prognosis, but no association between 25(OH)D
and disease status based on post-diagnostic blood samples [6,16].
There is a need, therefore, to further examine this relation in
prospective studies in which serum vitamin D levels were
measured prior to disease development. The purpose of this study
was to examine the association between prediagnostic serum
vitamin D [25(OH)D] and subsequent risk of melanoma in a
prospective study of older, middle-aged Finnish men.
Materials and Methods
Study population
We conducted a nested case-control study within the Alpha-
Tocopherol, Beta Carotene Cancer Prevention (ATBC) Study
cohort. The present analysis included 368 men; 92 participants
that developed melanoma and 276 matched (3:1 ratio) control
subjects to provide sufficient power to detect an odds ratio of 0.50
at 80% power (alpha=0.05). Incident cases, as defined by the
International Classification of Diseases 9 code (172, melanoma),
were diagnosed from April 1986 through April 2005. All
melanoma cases were identified through the Finnish Cancer
Registry, which provides close to 100% population-based cancer
ascertainment in Finland. Controls were selected from ATBC
Study participants that were alive at the time of the case diagnoses,
and were matched to each case based on age (+/23 years) and
date of baseline serum collection (+/230 days).
The ATBC Study was a randomized, controlled trial that
examined whether supplementation with alpha-tocopherol (vita-
min E) or beta-carotene would reduce the cancer incidence in
male smokers. Details have been previously reported [17], but in
brief, the study was conducted in southwestern Finland and
included 29,133 male smokers between the ages of 50–69 years,
who smoked at least five cigarettes a day, had no recent history of
cancer, severe illnesses (e.g., cirrhosis of liver, chronic renal
insufficiency, or other medical problems), or use of predefined
doses of vitamin E, A or beta carotene. The study was reviewed
and approved by the institutional review boards of the National
Public Health Institute in Finland and the U.S. National Cancer
Institute. All study participants provided written informed consent.
Study measures
At study entry, investigators administered questionnaires that
collected information on medical history and lifestyle behaviors,
including diet and smoking history. Height and weight were
measured using standard methods, and body mass index (BMI,
kg/m
2) was calculated. A follow-up questionnaire was adminis-
tered 3 years after baseline which ascertained information on skin
behavior (e.g., more prone to sunburn) and sun exposure.
Laboratory assays. Serum was collected at study entry,
stored at 270uC, and 25(OH)D levels were analyzed using the
LIAISON 25-OH Vitamin D Total Assay (DiaSorin, Inc.,
Stillwater, MN) at Heartland Assays, Inc. (Iowa). Matched case
and control samples were masked to case status and assayed in
batches. Quality control samples were 5% of the total number of
samples. Intrabatch and interbatch coefficients of variation (CV)
ranged between 9.3%–11.0% and 12.3%–13.6%, respectively.
Statistical analysis
Descriptive statistics were calculated for baseline characteristics
of participants by cancer status. The distribution of baseline
characteristics between cases and controls were compared using
the Wilcoxon rank-sum test for continuous variables and Chi-
square test for categorical variables.
Serum 25 (OH)D was modeled as three distinct categorical
variables: clinically-defined categories (,25, 25 to 37.49, 37.50 to
49.99 and 50+ nmol/L), season-specific quartiles, and quartiles of
season-adjusted residuals. The season-specific quartiles of 25
(OH)D were based on the distribution among control subjects
within the ‘‘darker’’ (November–April) and ‘‘lighter’’ (May–
October) months. The quartiles for the residuals of the season-
adjusted 25(OH)D values were obtained using a weighted
polynomial regression and modeling on log-transformed
25(OH)D levels that adjusted for date of blood draw [18].
Conditional logistic regression was used to obtain odds ratios
(ORs) and corresponding 95% confidence intervals (CIs) to
estimate the association between vitamin D levels and melanoma
risk. Potential confounders and variables associated with 25(OH)D
levels and/or melanoma were included in the initial model
building process. Variables that changed the ORs by 10% or more
were considered as potential confounders. Final parsimonious
models adjusted for age (continuous), date of serum collection, skin
behavior (burns easily: no/yes/missing), dietary cholesterol
(continuous), height (continuous), and weight (continuous). Effect
modification of cigarette smoking, BMI, height, leisure physical
activity, or trial supplementation was examined through inclusion
of a cross-product term in the model. Data were analyzed using
SASH (version 9.2, SAS Institute Inc., Cary, NC) and all P-values
were two-sided.
Results
Melanoma cases were taller, heavier, and more likely to have at
least an elementary school education than the controls (Table 1).
By contrast, cases had lower dietary intake of cholesterol and fish
and were less likely to have reported their skin type and whether or
not they had taken trips to the south. Serum 25(OH)D levels were
similar for cases and controls. The median age at diagnosis was 65
years; mean (standard deviation) was 66 (7.1) years. The median
time from baseline blood draw to diagnosis was 8.9 years. The
median follow-up time for the control subjects was 18.2 years.
We observed no association between serum 25(OH)D levels and
risk of melanoma (Table 2; Ptrends.0.05). For clinically-defined
categories, lower risk of melanoma was suggested for serum
vitamin D levels between 37.50 to 49.99 nmol/L, but then an
increased risk of melanoma for men whose vitamin D levels were
$50 nmol/L (ORs=0.60 and 1.32, with corresponding 95%
CIs=0.25–1.44 and 0.64–2.72, respectively) when compared to
men whose prediagnostic levels were ,25 nmol/L. Similarly,
season-specific quartiles showed a decreased risk of melanoma in
the second quartile (OR=0.79; 95% CI=0.34–1.81) and an
increased risk in the third quartile (OR=1.33; 95% CI=0.62–
2.85) when compared to the lowest quartile, albeit not statistically
significant. Season-adjusted residuals, however, suggested an
increased melanoma risk in the second and third quartiles
(ORs=1.20 and 1.56 with 95% CIs=0.55–2.64 and 0.74–3.28,
respectively). Tests for non-linear trends were not statistically
significant (P-values.0.05, data not shown), and there were no
significant interactions between circulating vitamin D levels and
the number of cigarettes smoked per day, BMI, height, leisure
physical activity, or trial supplementation (data not shown).
Discussion
The present study is the first to prospectively examine
prediagnostic serum vitamin D concentrations in relation to
subsequent risk of melanoma. Our findings indicate no statistically
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melanoma, although there was a suggested protective association
in the second quartiles compared to the lowest levels.
A previous population study examining vitamin D and non-
melanoma skin cancer (NMSC) showed high serum 25(OH)D
levels related to decreased risk of NMSC [19], while a case study of
14 melanoma patients found 25(OH)D serum levels ranged from
50 to 125 nmol/L, not supporting the hypothesis that deficient
levels are associated with the development of malignant melanoma
[20]. Our results are similar to those observed in a case-control
study showing median levels of serum 25(OH)D in melanoma
patients not significantly different from those of the controls (42 vs.
47 nmol/L; P=0.44) [16]. That study did, however, find median
levels to be significantly lower in patients with advanced
melanoma (stage IV, metastasized) than those with stage Ia/b
(33 vs. 41 nmol/L; P,0.01). Because we did not have disease stage
available, we were unable to examine potential associations
between serum vitamin D levels and risk of advanced melanoma
in the present analysis. Although previous prospective studies have
not examined risk of developing melanoma, associations between
serum vitamin D level and cancer risk have been reported, with a
potential U-shaped association suggested for prostate and
pancreatic cancer [11,21]. Reports from population-based studies
examining higher dietary or supplemental intake of vitamin D
have been inconsistent; some showing a reduced risk of melanoma
overall [22,23] and some showing no association [24,25]. It should
be noted, however, that dietary intakes of vitamin D are
notoriously difficult to assess and may not reflect accurate vitamin
D status.
A strength of our study is having examined serum 25(OH)D and
melanoma in a prospective cohort ensuring that our vitamin D
measure preceded the development of melanoma by up to 18
Table 1. Baseline characteristics of men, ATBC Study.
Characteristic Cases (N=92) Control (N=276) P -value*
Age at randomization (yrs) 57.5 (53.5–61.0) 57.0 (53.5–61.0) 0.97
Education.elementary school, n (%) 30 (32.6) 59 (21.4) 0.03
Married, n (%) 16 (17.4) 40 (14.5) 0.51
Height (cm) 176.0 (171.0–179.0) 173.0 (169.0–177.0) ,0.01
Weight (kg) 84.8 (77.8–90.5) 77.8 (70.1–86.1) ,0.01
BMI (kg/m
2) 26.5 (24.7–29.2) 26.1 (23.6–28.4) 0.07
Dietary Intake (per day)
Cholesterol (mg) 507.5 (380.4–596.9) 546.3 (417.5–738.3) 0.03
Energy (kcal) 2549.1 (2228.3–2953.9) 2691.7 (2224.8–3145.9) 0.21
Fish (g) 29.3 (19.9–45.3) 35.4 (22.1–54.5) 0.07
Total vitamin D (mg) 4.2 (3.1–6.4) 5.1 (3.6–6.5) 0.07
Total calcium (mg) 1426.0 (1056.1–1724.2) 1419.1 (1002.3–1794.7) 0.79
Alcohol intake (g) 88.1 (26.3–250.0) 91.7 (17.1–253.8) 0.98
Smoking history
No. cigarettes/d 20.0 (15.0–25.0) 20.0 (15.0–23.5) 0.42
No. years smoked 38.0 (30.5–42.0) 35.0 (30.0–42.0) 0.33
Physical activity-leisure, n (%) 0.95
Light 36 (39.1) 107 (38.8)
Moderate/heavy 56 (60.9) 169 (61.2)
Skin burns easily{, n (%) ,0.01
No 40 (43.5) 170 (61.6)
Yes 30 (32.6) 86 (31.2)
Missing 22 (23.9) 20 (7.2)
Trips south-daily sun exposure $1h r ,n( % ) ,0.01
None 42 (45.7) 141 (51.1)
$1 trip 28 (30.4) 118 (42.8)
Missing 22 (23.9) 17 (6.2)
Serum draw months{, n (%) 0.89
Light months 30 (32.6) 87 (31.5)
Dark months 62 (67.4) 189 (68.5)
Serum 25(OH)D (nmol/L) 33.1 (21.9–51.6) 31.8 (20.9–48.5) 0.56
Medians (25
th,7 5
th percentiles) are reported unless otherwise indicated.
*P-value for contrast between cases and controls by Wilcoxon rank sum test (medians) and Chi-square test (proportions).
{Skin behavior in prolonged direct sunlight (self-reported).
{Light months=May–October, dark months=November–April.
Information on skin behavior and sun exposure was ascertained from a follow-up questionnaire which was missing for some men.
doi:10.1371/journal.pone.0035112.t001
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Cancer Registry with approximately 100% case ascertainment.
Controls were matched to the cases by age and month of blood
collection, which likely reduced misclassification of vitamin D
status due to seasonal variation. A limitation of the study is a lack
of generalizability of the findings given that our study population
consists of older middle-aged Finnish male smokers; median age at
diagnosis was 65 years. We only had a single measure of serum
25(OH)D, however, which may not reflect long-term exposure and
did not allow us to examine changes in vitamin D concentration
levels over time although moderate correlations between measures
collected years apart have been reported elsewhere [26,27]. The
interpretation of the results is limited by the small number of cases
(n=92), which may have made detection of a significant
associations difficult. Further, we acknowledge that the Finnish
population used in the present analysis are known to have low
levels of serum 25(OH)D compared to U.S. study populations for
several reasons, including the substantially higher latitude of
Finland (60 degrees N), low dietary and minimal supplemental
intakes of vitamin D among the ATBC Study participants, and the
fact that blood samples were not collected during peak summer
vacation times (mid- June through August) because the study
clinics were effectively closed. It should be mentioned, however,
that there is ongoing debate regarding the definition of ‘‘sufficient’’
levels, with consensus not yet reached. For example, in the recent
IOM report, the committee’s review of data suggests that persons
are at risk of deficiency at serum 25(OH)D levels of below
30 nmol/L. Our cases and controls had median serum values of
approximately 32 nmol/L.
In conclusion, prediagnostic circulating vitamin D concentra-
tions were not associated with subsequent risk of melanoma.
Additional prospective studies are needed to investigate the
association between serum 25(OH) levels and risk of melanoma
in study populations that include nonsmokers and women, and
ideally, with a larger number of melanoma cases and data for stage
at diagnosis.
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